Aurocyclobenzaprine

The short version: aurocyclobenzaprine is a generic muscle relaxant with modest evidence for short-term muscle spasm and some evidence for fibromyalgia, but its risks—drowsiness, falls in the elderly, and serotonin syndrome—are real and often understated.

Aurocyclobenzaprine is the generic form of cyclobenzaprine, a centrally acting muscle relaxant. It works by blocking serotonin (5-HT2) receptors in the spinal cord, which depresses the stretch reflex that keeps muscles tense [2]. That mechanism is well-established from animal studies, but it also means the drug directly interferes with your nervous system's signaling, not just the muscle itself.

The evidence for benefit is thin. For acute muscle spasm, the drug was approved decades ago on short-term trials that mostly measured patient-reported improvement, not objective recovery. For fibromyalgia, a meta-analysis of 5 trials with 392 participants found "overall and symptom-specific improvements," but the same review notes that most standard drug therapies for fibromyalgia yield only modest pain relief with notable side effects [1]. The numbers are sobering: across drug classes, about 30-48% of patients get a 30% pain reduction on drug versus 20-34% on placebo, while dropout rates from side effects run 5-22% on drug versus 7-11% on placebo [1]. That means for every 100 people you treat, roughly 10-15 more get meaningful pain relief, but 5-10 more quit because of side effects.

The risks are not trivial. Cyclobenzaprine is chemically similar to tricyclic antidepressants and carries the same anticholinergic burden: sedation, dry mouth, blurred vision, constipation, and urinary retention. In elderly patients, these effects dramatically increase fall risk. One prospective study of 795 elderly fall patients found that drugs like cyclobenzaprine are among the neuroleptic-type medications that raise fall odds by over 3-fold [14]. A case report documents serotonin syndrome—a potentially life-threatening condition of agitation, fever, muscle rigidity, and rapid heart rate—in a 27-year-old woman who took 50-60 mg of cyclobenzaprine while on a standard SSRI dose [3]. That is an overdose, but the interaction risk is real at lower doses too.

The evidence base is old, mostly small, and funded by manufacturers who had no incentive to study long-term harms. The drug was approved before modern safety standards, and no large, long-term, independently funded trial has ever compared it to a true placebo in a general population. The most informative design—randomized, placebo-controlled, with hard outcomes like functional recovery or all-cause harm—was never run.

My call: for short-term (under 2 weeks) muscle spasm in a young, healthy adult who does not drive or operate machinery, the benefit may outweigh the risk. For fibromyalgia, the benefit is marginal and the side effect burden is high. For anyone over 65, or anyone on antidepressants, the risks of falls and serotonin syndrome likely outweigh any benefit. Confidence: moderate for acute use, low for fibromyalgia, high for the elderly risk.